An efficacy study of itraconazole in the treatment of Penicillium marneffei infection
- PMID: 1339213
An efficacy study of itraconazole in the treatment of Penicillium marneffei infection
Abstract
Objectives: to evaluate the efficacy and safety of itraconazole in treating P. marneffei infection.
Methods: Ten patients with previously untreated P. marneffei infection were given oral itraconazole at a dose of 200 mg twice a day for 2 months, followed by a dose of 100 mg once a day for 1 month. Efficacy was determined by the clinical and microbiological cure.
Results: All but one patient were seropositive for human immunodeficiency virus (HIV). Two patients died during therapy. Clinical improvement was evident in 8 patients. In 7 of these, the mean duration for becoming culture negative was 57 days. Five patients presented with relapse of P. marneffei infection within four months after completion of treatment.
Conclusions: Itraconazole was shown to be effective in the initial treatment of P. marneffei infection. Relapse after treatment is common and long-term suppressive therapy is recommended.
Similar articles
-
A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus.N Engl J Med. 1998 Dec 10;339(24):1739-43. doi: 10.1056/NEJM199812103392403. N Engl J Med. 1998. PMID: 9845708 Clinical Trial.
-
Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients.Am J Trop Med Hyg. 2007 Aug;77(2):350-3. Am J Trop Med Hyg. 2007. PMID: 17690411
-
A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand.Clin Infect Dis. 2002 Jan 15;34(2):277-84. doi: 10.1086/338154. Epub 2001 Dec 7. Clin Infect Dis. 2002. PMID: 11740718 Clinical Trial.
-
Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review.Br J Clin Pract Suppl. 1990 Sep;71:118-22. Br J Clin Pract Suppl. 1990. PMID: 1965415 Review.
-
Disseminated Penicillium marneffei infection as an imported disease in HIV-1 infected patients. Description of two cases and a review of the literature.Neth J Med. 1994 Jan;44(1):18-22. Neth J Med. 1994. PMID: 8202201 Review.
Cited by
-
An Overlooked and Underrated Endemic Mycosis-Talaromycosis and the Pathogenic Fungus Talaromyces marneffei.Clin Microbiol Rev. 2023 Mar 23;36(1):e0005122. doi: 10.1128/cmr.00051-22. Epub 2023 Jan 17. Clin Microbiol Rev. 2023. PMID: 36648228 Free PMC article. Review.
-
Is stopping secondary prophylaxis safe in HIV-positive talaromycosis patients? Experience from Myanmar.HIV Med. 2020 Nov;21(10):671-673. doi: 10.1111/hiv.12921. Epub 2020 Aug 1. HIV Med. 2020. PMID: 32741092 Free PMC article.
-
An Overview of Diagnostic and Management Strategies for Talaromycosis, an Underrated Disease.J Fungi (Basel). 2023 Jun 6;9(6):647. doi: 10.3390/jof9060647. J Fungi (Basel). 2023. PMID: 37367583 Free PMC article. Review.
-
Penicillium marneffei Infection in AIDS.Patholog Res Int. 2011 Feb 10;2011:764293. doi: 10.4061/2011/764293. Patholog Res Int. 2011. PMID: 21331327 Free PMC article.
-
Clinical features of talaromycosis in people living with HIV/AIDS (PWHA) and patients with anti-interferon-γ autoantibodies.PLoS Negl Trop Dis. 2025 May 9;19(5):e0012992. doi: 10.1371/journal.pntd.0012992. eCollection 2025 May. PLoS Negl Trop Dis. 2025. PMID: 40344159 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical